این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Public Health، جلد ۵۲، شماره ۱۱، صفحات ۲۴۱۲-۲۴۱۶
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Lncrna FGFR3-AS1 Is a Prognostic Indicator for Ovarian Cancer and Induces Cell Proliferation and Hinders Apoptosis
چکیده انگلیسی مقاله Background: Ovarian cancer is one of the most common malignant tumors in Gynecology, whose treatment was seriously limited by the unclear understanding of molecular mechanism in disease development. LncRNA FGFR3-AS1 is involved in human cancers. In this study, we aimed to clarify its regulatory effect on ovarian cancer. Methods: Ovarian cell model was used in 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide (MTT) assay and flow cytometry for investigating the role of LncRNA FGFR3-AS1 in ovarian cancer. Western blot detection (CCND1、CDK6、MAPK9 and PIK3CA) tumor regulatory proteins. The study was conducted between March 2020 and October 2022 at General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, China. Results: The results demonstrated the upregulation of LncRNA FGFR3-AS1 in ovarian cancer, whose expression was positively related to tumor grade and AJCC stage, and negatively correlated with patients’ prognosis. LncRNA FGFR3-AS1 promoted ovarian cancer development through promoting cell growth and inhibiting cell apoptosis. PI3K signaling pathway-related proteins may be implicated in the LncRNA FGFR3-AS1 induced regulation of ovarian cancer. Conclusion: LncRNA FGFR3-AS1 was involved in the development of ovarian cancer, which has the potential to become therapeutic target and prognostic indicator in ovarian cancer treatment.  
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Yuyang Zhang
The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China


| Lili Sun
The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China


| Tieshuang Chen
The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China


| Yuanyuan Yue
The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China


| Lin Zhao
The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China


| Dan Zhang
Department of Gynecology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, Liao-ning Province 113008, China
نشانی اینترنتی https://ijph.tums.ac.ir/index.php/ijph/article/view/31532
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات